ROS1 and melanoma: Generally, no significant difference in OS was observed among the ROS1 mutation, the wild-type, and the fusion subgroups in the pooled population (P = 0.531, Figure 2C); likewise, as for the non-ICI treated melanoma patients, ROS1 mutation demonstrated similar OS as the wild-type counterpart (HR 0.80, 95% CI 0.22–2.90; P = 0.737, Figure 2D).